does medicare cover glp-1 for weight loss will drugs starting on July 1. Obesity is a known risk factor for at least 13 cancer types, and early research shows that GLP-1s may help The GLP-1 Access Gap: Mapping

FDA M9-Biopharmaceutics-Classification-System-Based-Biowaivers.pdf

These findings suggest an essential role for endogenous GLP-1 receptor signaling in the control of bone resorption

People looking for simple, transparent pricing might find Found frustrating

#BMS #Cobenfy #schizophrenia #psychiatry Biotech Executive, Thought Leader & Creator | Diagnostics Executive | Microfluidics & Immunoassay Innovation | FDA Strategy Led EUA 230055, EUA 240006 & 510(k) K240728 | Oncology, AIBiology & IVD Commercialization Market Watch | Bristol Myers Squibbs Cobenfy Faces Uptake Challenges Amid Strong Q3 Earnings Bristol Myers Squibb ($BMY) reported $12.2B in Q3 revenue, surpassing analyst expectations yet investor attention centered on Cobenfy, the first new schizophrenia drug in 35 years, which posted $43M in sales, slightly below forecasts

Viebahn GK, Khurana A, Freund L, et al

Eric Xu Qilu Regor Therapeutics Inc., 1206 Zhangjiang Road, Building C, Pu Dong New District, Shanghai, 201210, China Wei Huang, Wei Guo, Xianqiang Sun, Wenge Zhong & Daopeng Yuan Regor Pharmaceuticals Inc., 50 Soldiers Field Pl, Boston, MA, 02135, USA Feng Liu Authors Honglei Ma Wei Huang Xiaoxi Wang Lihua Zhao Yi Jiang Feng Liu Wei Guo Xianqiang Sun Wenge Zhong Daopeng Yuan H